Jun 16, 2020
Whole in One: Treat Enlarged Pores and Give Your Skin an Overall Boost
Jun 10, 2020
Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris
May 29, 2020
Menlo Therapeutics Receives FDA Approval of ZILXI(TM) (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea
May 14, 2020
2020 Insights into the U.S. Rosacea Market: Profiles of Key Players Including Allergan, Galderma and Sol-Gel Technologies
May 07, 2020
Accure Receives CE Mark Approval for First-Ever 1726nm Laser Platform to treat Acne
May 07, 2020
Acne Market Review 2016-2019 and Forecast to 2024
Apr 09, 2020
Global Dermatologicals Market is Expected to Reach $36.2 Billion by 2026
Feb 18, 2020
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
Feb 11, 2020
Dermata Therapeutics Announces Completion of Enrollment in a Phase 2b Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris
Feb 06, 2020
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology
Jan 14, 2020
Foamix Announces AMZEEQ(TM) (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.
Jan 13, 2020
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO(TM) (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)
Dec 19, 2019
FDA Approves Ortho Dermatologics' ARAZLOTM (Tazarotene) Lotion, 0.045%, For Acne Vulgaris
Dec 04, 2019
Global $5.12 Bn Acne Treatment Market Opportunities and Forecast to 2024
Nov 04, 2019
Foamix Announces Publication of AMZEEQ(TM) (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology
Oct 25, 2019
Sebacia Reports New Long-Term Real-World Results Demonstrating 92% Average Improvement in Acne at 24 Months
Oct 24, 2019
Sebacia Announces Oral Presentations Reporting 24-Month EU Real-World Data and 3-Month U.S. Real-World Data of Sebacia Microparticles at ASDS Annual Meeting 2019
Oct 18, 2019
Foamix Receives FDA Approval of AMZEEQ(TM) Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
Oct 17, 2019
Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea
Oct 10, 2019
Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference